January 10, 2007 — Transdermal rotigotine, a dopamine agonist, is effective in controlling symptoms of early-stage Parkinson's disease (PD), a new study suggests. The multicenter, randomized, ...
Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...
A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the ...
May 1, 2012 (New Orleans, Louisiana) — A transdermal patch that delivers 8 mg of the dopamine-receptor agonist rotigotine (Neupro, UCB) in a once-daily, single application is the lowest effective dose ...
Researchers conducted a randomized clinical trial to assess whether 24 weeks of treatment with rotigotine can modify cognitive functions in patients with mild to moderate Alzheimer disease. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback